Looking to March 23, the FDA released a question-and-answer guidance document for industry about the upcoming transition for how certain products will now be approved under a biological pathway, including exceptions to the transition and how companies will receive notifications about their applications.
The FDA Wednesday released a question-and-answer guidance document for industry about the upcoming transition for how certain products will now be approved under a biological pathway, including exceptions to the transition and how companies will receive notifications about their applications.
The nonbinding final industry guidance, “The ‘Deemed to be a License’ Provision of the BPCI Act: Questions and Answers” represents the FDA’s current thinking as it implements the “transition” provision of the of the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
The document aims to facilitate transition planning and describes FDA’s compliance policy for the labeling of biological products that are the subject of deemed biologics license applications (BLAs). Besides insulin, other biological products affected by the transition include human growth hormone (somatropin), pancrelipase, chorionic gonadotropin, follitropin alfa, and menotropins.
An application for a biological product previously approved under section 505 of the Federal Food, Drug, and Cosmetic Act will change on March 23 and will be deemed to be a license for the biological product under section 351 of the Public Health Service (PHS) Act. Last month, the FDA issued a final rule on the definition of the term “biological product.” The FDA said it was no longer necessary to include the interpretation of the term “chemically synthesized polypeptide” as first proposed in December 2018.
The document lays out certain exceptions to the transition period and also how such products will be identified.
The BPCIA is “silent regarding the process for accomplishing the transition of approved NDAs to deemed BLAs,” the document noted. The FDA intends to send a letter to those application holders on March 23 advising that the approved NDA was deemed to be a BLA at 12:00 am Eastern Daylight Time on March 23 and no longer exists as an NDA.
If the NDA is approved on March 23, the approved NDA will be deemed to be a BLA immediately after approval.
Three questions address situations of particular interest to developers:
The document addresses things like application numbers, license numbers, program fees, withdrawals of applications, and labeling requirements. It also discusses supplements to applications, including changes to manufacturing sites, comparability data, batch analysis data, appropriate stability data, and facility inspections.
It also includes information about the transition from the Orange Book to the Purple Book and about the designation of proper names.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.